Neoadjuvant cancer therapeutic strategy has been explored in phase I/II clinical studies for head and neck squamous cell carcinoma. Here this group reports a single-arm, phase II clinical trial evaluating the neoadjuvant radiotherapy plus PD-1 inhibitor tislelizumab combined with paclitaxel and cisplatin, followed by radical surgical resection on 28 patients with untreated stage III-IVB head and neck squamous cell carcinoma.
- Zhigang Liu
- Dong Wang
- Wen Jiang
